By David DolanThe Breast Growth Management Association, the breast cancer advocacy group, has recently been in the news for a number of events.
The group, which advocates for patients’ rights and medical care for those with breast cancer, recently posted a petition urging the FDA to require the FDA-approved medication to be labeled.
The petition, which garnered over 60,000 signatures, was prompted by a statement by the group’s president, Julie Jaffe, in which she said that the FDA has not adequately studied breast cancer treatment and the “growing body of evidence indicates that there is little or no benefit from the drug.”
“We urge the FDA, in light of the mounting evidence that there may be no benefit, to require breast growth medication labeling as a standard for labeling,” Jaffe said in the statement.
Jaffe also said that if the FDA required labeling, patients should be allowed to seek reimbursement from the companies that manufacture the drug.
The FDA, however, has said that it would not require the labeling of the drug, but rather wait for clinical trials and data from the manufacturer.